Profectus BioSciences and Vyriad have entered into a collaboration to develop oncolytic recombinant vesicular stomatitis virus (rVSV) vaccines for cancer immunotherapy.

Through the collaboration, the companies will use their respective rVSV-derived oncolytic and vaccine platform technologies to develop novel cancer drugs.

Vyriad’s rVSV-derived oncolytic viruses are engineered to infect, selectively replicate in, and destroy cancer cells, and Profectus’ rVSV-derived VesiculoVax vaccine vectors are engineered to prime the immune system to generate a robust and durable cellular immune response to promote sustained cancer cell-destroying activity.

“We are confident that this critical alliance will allow us to unleash the full power of oncolytic immunovirotherapy.”

The oncolytic vaccines being developed would selectively destroy tumour cells while boosting patients’ immune systems to continue killing any residual cancer cells that may survive the initial virus attack.

Profectus president Jeffrey Meshulam said: "Vyriad was the first to develop and clinically test rVSV as an oncolytic agent. We look forward to working closely with the Vyriad team to advance innovative new vesiculovirus-based oncolytic vaccines that have clear potential to benefit cancer patients."

Though VSVs are not considered human pathogens, they can be engineered to selectively replicate in tumour cells and destroy them without harming healthy cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The oncolytic vesiculoviruses have demonstrated the ability to target and destroy cancer cells while also stimulating the body’s adaptive anti-tumour immune response that directs the immune system to continue killing cancer cells.

This anti-tumour immune response is more powerfully stimulated when the virus has been further engineered to encode a tumour antigen, the companies said.

Vyriad president and CEO Stephen J Russell said: "We are confident that this critical alliance will allow us to unleash the full power of oncolytic immunovirotherapy as a new and highly versatile anticancer modality."

The first human clinical trials to evaluate the safety and efficacy of the vaccines would begin next year.

Financial terms of the agreement have not been disclosed.